Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 2

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
Item 1.    Financial Statements.

10x Genomics, Inc.

Condensed Consolidated Balance Sheets

 (In thousands)

September 30,2025December 31,2024(Unaudited)(Note 1)AssetsCurrent assets:Cash and cash equivalents$432,508 $344,067 Marketable securities49,576 49,335 Accounts receivable, net43,779 87,862 Other receivables52,813 606 Inventory61,956 83,107 Prepaid expenses and other current assets19,195 19,410 Total current assets659,827 584,387 Property and equipment, net232,534 252,648 Restricted cash201 — Operating lease right-of-use assets63,650 57,290 Goodwill4,511 4,511 Intangible assets, net64,759 15,671 Other noncurrent assets1,879 4,129 Total assets$1,027,361 $918,636 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$18,069 $12,909 Accrued compensation and related benefits37,084 33,615 Accrued expenses and other current liabilities35,766 41,165 Deferred revenue22,139 20,658 Operating lease liabilities10,543 9,286 Contingent consideration, current23,723 — Total current liabilities147,324 117,633 Contingent consideration, noncurrent1,210 — Operating lease liabilities, noncurrent76,442 73,327 Deferred revenue, noncurrent10,871 12,513 Other noncurrent liabilities6,394 5,029 Total liabilities242,241 208,502 Commitments and contingencies (Note 6)Stockholders’ equity:Preferred stock— — Common stock2 2 Additional paid-in capital2,279,319 2,177,672 Accumulated deficit(1,494,339)(1,467,047)Accumulated other comprehensive income (loss)138 (493)Total stockholders’ equity785,120 710,134 Total liabilities and stockholders’ equity$1,027,361 $918,636      The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Table of Contents

10x Genomics,